| IMORX | RPTIX | IMORX / RPTIX | |
| Total Expense Ratio | 1.44 | 0.63 | 229% |
| Annual Report Gross Expense Ratio | 1.44 | 0.63 | 229% |
| Fund Existence | 14 years | 10 years | - |
| Gain YTD | 6.575 | 3.369 | 195% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 500000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 681M | 25.9B | 3% |
| Annual Yield % from dividends | 0.00 | 0.05 | - |
| Returns for 1 year | -9.54 | -8.70 | 110% |
| Returns for 3 years | 23.56 | 10.44 | 226% |
| Returns for 5 years | -27.34 | -6.04 | 453% |
| Returns for 10 years | -19.72 | 31.48 | -63% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AMDG | 45.02 | 6.83 | +17.88% |
| Leverage Shares 2X Long AMD Daily ETF | |||
| HQL | 16.98 | 0.22 | +1.31% |
| abrdn Life Sciences Investors | |||
| BTA | 9.56 | 0.01 | +0.10% |
| Blackrock Long-Term Municipal Advantage Trust | |||
| JMST | 50.92 | 0.01 | +0.02% |
| JPMorgan Ultra-Short Municipal Inc ETF | |||
| HELX | 34.90 | N/A | N/A |
| Franklin Genomic Advancements ETF | |||